Literature DB >> 27649293

Trends and Outcomes of Patent Ductus Arteriosus Treatment in Very Preterm Infants in Canada.

Armend Lokku1, Lucia Mirea2, Shoo K Lee1, Prakeshkumar S Shah1.   

Abstract

Objective To assess trends in patent ductus arteriosus (PDA) management and examine concurrent changes in neonatal mortality and morbidities. Methods This retrospective observational study examined infants born at 23 to 32 weeks' gestational age with PDA and admitted to a neonatal unit during 2006 to 2012. Multivariable logistic regression assessed trends in yearly PDA treatment rates and compared a composite outcome of mortality or any severe morbidity (bronchopulmonary dysplasia, intraventricular hemorrhage, periventricular leukomalacia, retinopathy of prematurity, or necrotizing enterocolitis) between and within time periods and PDA treatments. Results Study subjects included 5,824 preterm neonates with clinical/echocardiographic PDA diagnosis. During 2006 to 2012, conservative management increased (14-38%), whereas pharmacotherapy-only (58-49%), surgical ligation-only (7.1-2.5%), and both pharmacotherapy and surgical ligation (21-10%) decreased (p-values <0.01). From 2006 to 2008 and 2009 to 2012, the composite outcome decreased for infants managed conservatively (AOR = 0.70, 95% CI 0.52-0.92), with no changes detected for pharmacotherapy and/or ligation. Lower composite outcome after conservative management versus pharmacotherapy-only during 2009 to 2012 (AOR = 0.61, 95% CI 0.51-0.74), but not during 2006 to 2008 reflect significant effect modification by time period. Conclusion In Canada, during 2006 to 2012, conservative PDA management increased while pharmacotherapy and/or surgical ligation decreased. Lower composite outcome was detected during later years after increases in conservative management; however, bias due to unmeasured confounders remains possible. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2016        PMID: 27649293     DOI: 10.1055/s-0036-1593351

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  21 in total

1.  Genetic variants associated with patent ductus arteriosus in extremely preterm infants.

Authors:  John M Dagle; Kelli K Ryckman; Cassandra N Spracklen; Allison M Momany; C Michael Cotten; Joshua Levy; Grier P Page; Edward F Bell; Waldemar A Carlo; Seetha Shankaran; Ronald N Goldberg; Richard A Ehrenkranz; Jon E Tyson; Barbara J Stoll; Jeffrey C Murray
Journal:  J Perinatol       Date:  2018-12-05       Impact factor: 2.521

2.  Association of Patent Ductus Arteriosus Ligation With Death or Neurodevelopmental Impairment Among Extremely Preterm Infants.

Authors:  Dany E Weisz; Lucia Mirea; Erin Rosenberg; Maximus Jang; Linh Ly; Paige T Church; Edmond Kelly; S Joseph Kim; Amish Jain; Patrick J McNamara; Prakesh S Shah
Journal:  JAMA Pediatr       Date:  2017-05-01       Impact factor: 16.193

3.  Treatment and Nontreatment of the Patent Ductus Arteriosus: Identifying Their Roles in Neonatal Morbidity.

Authors:  Ronald I Clyman; Melissa Liebowitz
Journal:  J Pediatr       Date:  2017-07-11       Impact factor: 4.406

4.  Prophylactic Indomethacin Compared with Delayed Conservative Management of the Patent Ductus Arteriosus in Extremely Preterm Infants: Effects on Neonatal Outcomes.

Authors:  Melissa Liebowitz; Ronald I Clyman
Journal:  J Pediatr       Date:  2017-04-07       Impact factor: 4.406

5.  Patent Ductus Arteriosus and the Effects of Its Late Closure in Preterm Infants with Severe Bronchopulmonary Dysplasia.

Authors:  Sophia M Ansems; Haresh Kirpalani; Laura Mercer-Rosa; Yan Wang; Rachel K Hopper; María V Fraga; Erik A Jensen
Journal:  Neonatology       Date:  2019-07-03       Impact factor: 4.035

Review 6.  Patent Ductus Arteriosus of the Preterm Infant.

Authors:  Shannon E G Hamrick; Hannes Sallmon; Allison T Rose; Diego Porras; Elaine L Shelton; Jeff Reese; Georg Hansmann
Journal:  Pediatrics       Date:  2020-11       Impact factor: 7.124

7.  Trends in transcatheter and operative closure of patent ductus arteriosus in neonatal intensive care units: Analysis of data from the Pediatric Health Information Systems Database.

Authors:  Michael L O'Byrne; Marisa E Millenson; Connor B Grady; Jing Huang; Nicolas A Bamat; David A Munson; Lihai Song; Yoav Dori; Matthew J Gillespie; Jonathan J Rome; Andrew C Glatz
Journal:  Am Heart J       Date:  2019-08-17       Impact factor: 4.749

8.  Relative effectiveness and safety of pharmacotherapeutic agents for patent ductus arteriosus (PDA) in preterm infants: a protocol for a multicentre comparative effectiveness study (CANRxPDA).

Authors:  Souvik Mitra; Amish Jain; Joseph Y Ting; Nadya Ben Fadel; Christine Drolet; Ayman Abou Mehrem; Amuchou Soraisham; Bonny Jasani; Deepak Louis; Anie Lapointe; Jon Dorling; Faiza Khurshid; Abbas Hyderi; Kumar Kumaran; Jaya Bodani; Dany Weisz; Ruben Alvaro; Mohammed Adie; Miroslav Stavel; Alyssa Morin; Soume Bhattacharya; Jaideep Kanungo; Rody Canning; Xiang Y Ye; Tara Hatfield; Courtney E Gardner; Prakesh Shah
Journal:  BMJ Open       Date:  2021-05-05       Impact factor: 2.692

Review 9.  Patent ductus arteriosus in preterm infants: is early transcatheter closure a paradigm shift?

Authors:  P Vali; S Lakshminrusimha; A Pelech; M Underwood; F Ing
Journal:  J Perinatol       Date:  2019-09-27       Impact factor: 3.225

10.  Early treatment versus expectative management of patent ductus arteriosus in preterm infants: a multicentre, randomised, non-inferiority trial in Europe (BeNeDuctus trial).

Authors:  Tim Hundscheid; Wes Onland; Bart van Overmeire; Peter Dijk; Anton H L C van Kaam; Koen P Dijkman; Elisabeth M W Kooi; Eduardo Villamor; André A Kroon; Remco Visser; Daniel C Vijlbrief; Susanne M de Tollenaer; Filip Cools; David van Laere; Anne-Britt Johansson; Catheline Hocq; Alexandra Zecic; Eddy Adang; Rogier Donders; Willem de Vries; Arno F J van Heijst; Willem P de Boode
Journal:  BMC Pediatr       Date:  2018-08-04       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.